Fulvestrant + Abemaciclib
The combination of abemaciclib and fulvestrant shows promising efficacy and manageable toxicity in HR-positive advanced or recurrent endometrial cancer, especially in CN-L/NSMP tumors
Study Summaries
CHIPOR Trial: Secondary Debulking and HIPEC in Platinum Sensitive Recurrence
HIPEC combined with cytoreductive surgery significantly improved overall survival and progression-free survival in recurrent ovarian cancer
PAOLA-1: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer (Overall Survival)
Olaparib combined with bevacizumab provided a OS benefit for HRD-positive ovarian cancer patients.
Keynote B-21: Pembrolizumab vs. Placebo in High-risk Endometrial Cancer
Adjuvant Pembrolizumab did not improve DFS in high-risk endometrial cancer population
Korean HIPEC trial - IDS patients only 2023
HIPEC combined with ICS significantly improved PFS and OS in advanced-stage ovarian cancer patients, without increasing the rate of severe postoperative complications. A notable reduction in peritoneal recurrence may contribute to the OS improvement.
Korean HIPEC trial
The addition of HIPEC after interval cytoreductive surgery following neoadjuvant chemotherapy provided significant improvements in PFS and OS.
Interlace Trial
Induction chemotherapy followed by chemoradiotherapy significantly improves both progression-free survival and overall survival in patients with locally advanced cervical cancer compared to chemoradiotherapy alone.
COMPASSION 16
Cadonilimab potentially offers better PFS than pembrolizumab and atezolizumab therapies in recurrent advanced metastatic cervical cancer
GOG 241: Phase III Randomized Trial in Patients with Mucinous Epithelial Ovarian Cancer
Neither oxaliplatin-capecitabine nor bevacizumab significantly improved OS or PFS compared to paclitaxel-carboplatin in advanced-stage mucinous ovarian cancer.
GOG 205: Radiation for Locally Advanced Vulvar Cancer
The combination of radiation therapy with weekly cisplatin chemotherapy is effective in achieving high complete clinical and pathological response rates with manageable toxicity for the treatment of locally-advanced vulvar carcinoma.